Abstract. Plasmodium falciparum-induced anemia was characterized in Aotus monkeys repeatedly immunized by infection with P. falciparum (FVO strain) parasites, then cross-challenged with CAMP strain, or in monkeys receiving blood stage challenges as part of malaria vaccine trials. In 4 studies, 25 (30.5%) of 82 monkeys had at least a 50% reduction in hematocrit; mean day of maximum parasitemia was 12.5, whereas the mean day of minimum hematocrit was 18.8 (P < 0.0009). Decreased hematocrit levels were not associated with reticulocytosis until parasite densities decreased significantly from peak levels. Direct antibody tests to detect IgG and C3d on the surface of erythrocytes were negative. Nonantibody/noncomplement-mediated lysis of uninfected erythrocytes seems to be the principal cause of the anemia, and it also seems that bone marrow suppression and lysis of infected erythrocytes contributed to the anemia. Partial immunity-whether induced by repeated immunization with whole parasites or with vaccine-seems important to the development of anemia.
INTRODUCTION
Anemia is an important contributor to malaria's morbidity and mortality. In humans, several factors contribute to the development of malarial anemia. There is evidence that both parasitized and nonparasitized erythrocytes are lysed, but what part autoimmune hemolysis or other immunemediated events contribute to this lysis is unclear. Decreased erythrocyte production is also an important contributor to this anemia. Suppressive autologous serum factors, reduced erythropoietin synthesis, and alterations in cytokine production may be part of anemia development. 1 Not only does it seem that the anemia of malaria is caused by more than one factor, but there are also different forms of malarial anemia. In their study of anemia in young Gambian children, Abdalla and others 2 were able to divide the subjects into 3 groups (acute malaria, anemic acute malaria, and chronic anemic malaria), depending on factors such as history, parasitemia density, degree of illness, and hemoglobin concentration.
Aotus monkeys can be infected with Plasmodium falciparum and are thought to be an important model system in the development of blood-stage P. falciparum malaria vaccines. 3 The development of marked anemia in this model suggests that study of this vaccine in a primate model may yield information useful in understanding the anemia often seen in humans subjected to malaria transmission under natural conditions. In addition, the development of anemia during vaccine trials requires careful evaluation in order to rule out a specific immunogen as a contributor to the induction of anemia.
We report our evaluations of anemia observed in Aotus monkeys immunized to P. falciparum blood stage parasites of one strain (FVO) by repeated infection with that strain, then cross-challenged with another strain of P. falciparum (CAMP). We also noted cases of anemia in Aotus monkeys in 2 different P. falciparum vaccine efficacy trials. We have used these experimental opportunities to describe the natural history of P. falciparum-induced anemia in Aotus monkeys and to contribute to the understanding of its causes.
MATERIALS AND METHODS

Repeated infection of
Aotus lemurinus lemurinus with homologous and heterologous strains of P. falciparum. Aotus lemurinus lemurinus monkeys (n ‫ס‬ 8) are indigenous to Panama. They were housed at the Gorgas Memorial Institute, Panama City, Panama, and received their first P. falciparum (FVO strain) challenges between October 1994 and August 1995; they then received 6 more FVO challenges, each separated by ∼ 5 months, until all the animals had received 7 FVO challenges. All animals received their seventh FVO challenge simultaneously. Five weeks after the seventh FVO challenge and 2 weeks before challenge with the heterologous CAMP, all animals were treated orally once a day for 5 days with 50 mg/kg quinine and 6 mg/kg doxycycline to eliminate any occult FVO parasitemia. All then received the heterologous P. falciparum (CAMP strain) challenge 10 days after treatment was concluded. Three naïve control animals were included in the P. falciparum (CAMP strain) challenge. All challenges described in this study were performed by intravenous injection via the saphenous vein of 10 4 parasitized Aotus erythrocytes. 4 The 11 animals were assessed daily for 35 days for parasitemia, hematocrit levels were assessed on days 10, 14, 17, 21, 24, 28, 31, and 35 . Differences between the FVO and CAMP strains have been previously described.
livered with plasmid encoding Aotus granulocyte monocytecolony stimulating factor. DNA vaccines were administered by intradermal inoculation while EBA-175 region II protein 6 or phosphate-buffered saline (PBS) control emulsified in Montanide ISA 720 were administered, half subcutaneously, half intramuscularly. 5 Vaccine trial 1-first challenge and follow-up. On day 0, 28 days after the last dose of vaccine, 5 1 mL of acid-citratedextrose (Red Cross, Rockville, MD) decoagulated blood was removed from a single donor monkey with a P. falciparum (FVO strain) parasitemia. The blood was diluted with RPMI 1640 medium at 37°C, and the 32 experimental monkeys were injected intravenously with 10 4 parasitized erythrocytes. The first challenge occurred in January 1999. Monkeys were monitored daily for parasites, starting on day 2. The daily blood films for parasite enumeration were prepared from blood taken from the saphenous vein. Parasitemia and hematocrit levels were evaluated daily. Sera were collected 2 and 4 weeks after challenge.
Vaccine trial 1-second challenge and follow-up. Nine months after the first challenge (October 1999) and 10 months after the last dose of vaccine, a second challenge was conducted identically to the first challenge, except that each monkey received 10 5 parasitized erythrocytes. Twenty-four of the original 32 monkeys were included in this challenge. Second challenge follow-up was the same as first challenge follow-up, except that a direct antibody test (DAT) was performed every third day and blood films for reticulocyte counts were prepared daily.
Vaccine trial 2 with challenge. A total of 18 male and female Aotus nancymae monkeys were used in this study. The monkeys were supplied by the Center for the Reproduction and Conservation of Nonhuman Primates, Iquitos, Peru. Male and female pairs were randomly divided into 3 groups of 6 monkeys. Briefly, the monkeys received a total of 500 g DNA encoding region II of P. falciparum EBA-175, or control plasmid not encoding P. falciparum antigen. Both were delivered with plasmid-encoding Aotus granulocyte monocyte-colony stimulating factor. DNA vaccines were administered by intradermal inoculation. EBA-175 region II protein or PBS control emulsified in Montanide ISA 720 were administered half subcutaneously and half intramuscularly. Groups 1 (vaccine) and 2 (control) received 4 immunizations at weeks 0, 4, 8, and 24, whereas group 3 (vaccine) received its immunizations at weeks 12, 16, 20, and 24. All 3 groups were challenged simultaneously with 10 4 P. falciparum (FVO strain).
Vaccine trial 2-challenge and follow-up. On day 0, the experimental monkeys were infected from a single donor monkey with 10 4 parasitized erythrocytes in the same manner as the challenges in vaccine trial 1. The challenge occurred in July 2000. Monkeys were monitored daily beginning on day 2 for parasitemia, hematocrit level, and reticulocyte count. Modified DAT was performed every 4 days, and a complete blood count (CBC) was performed on days 2, 9, 17, and 24.
Treatment standards during vaccine trials 1 and 2. Infected monkeys were treated with mefloquine (20 mg/kg orally, single dose) if the parasitized erythrocytes rose to 300,000 parasites/L (6% when erythrocyte count was 5 × 10 6 /L), if the hematocrit decreased by < 50% over preinfection values, or if other untoward clinical signs were observed, such as anorexia or reduced physical activity. The monkeys not requiring treatment during follow-up were treated on day 28 with mefloquine.
Hematologic, parasitology, and immunologic tests. Parasite enumeration. Parasites were counted by means of the EarlePerez method. 7 Ten microliters of blood was dispensed onto a measured area of a microscope slide. A microscope with a known field of view diameter was used, and parasite densities were calculated and expressed as parasites per microliter of blood.
Hematocrit levels. Approximately 50 L of blood was allowed to flow into a microcapillary tube containing heparin. The tube was then spun for 5 minutes in a dedicated microhematocrit centrifuge, and the percentage hematocrit was determined with an IEC microhematocrit reader.
Direct antibody technique. We tested for the presence of immunoglobulin (Ig) G on the surface of Aotus erythrocytes with a gamma-ReACT test kit (Gamma Biologicals Inc., Houston, TX) for detection of IgG on the surface of erythrocytes. Both protein A and protein G are covalently linked to an insoluble matrix in a microcolumn. Aotus blood samples are placed at the top of the microcolumn, then centrifuged. IgG on the surface of any erythrocytes is bound by the protein A and protein G, and these cells do not transit the microcolumn during centrifugation. When erythrocytes from 44 patients with positive tube agglutination DATs were tested in this affinity microcolumn DAT, 29 (66%) of 44 were positive. 8 This microcolumn technique has 2 important advantages over convention tube techniques: first, it uses only 25 L of blood, an important issue with Aotus monkeys; and second, it does not rely on anti-human IgG, so there are no concerns about the degree of cross-reactivity between antihuman IgG and the Aotus IgG it is targeting.
Modified direct antibody technique. The protein A and G columns were modified by the addition of IgG directed against either human IgG or human complement C3d. Control studies indicated that the test did react with Aotus IgG.
Reticulocytes. New methylene blue-stained thin blood films were prepared, and the percentage reticulocytosis was determined microscopically on the basis of a count of 1,000 erythrocytes. Reticulocyte counts were corrected for anemia per Hutchison and Davy. 9 Complete blood counts. Complete blood counts were performed with a Coulter Counter, model JT W/IR.
Enzyme-linked immunosorbent assay. Serum antibodies were assayed as previously described. 10 Purified baculovirus recombinant EBA-175 region II protein (1 g/mL) in PBSsodium azide buffer was used as capture antigen, The enzyme-linked immunosorbent assay results ae reported as the interpolated reciprocal dilution estimated to give an optical density of 0.5.
Statistical analysis. Statistical tests were performed by SPSS for Windows, version 8 (SPSS Inc., Chicago, IL).
RESULTS
Aotus immunized by repeated infection. After the CAMP challenge, mean hematocrit levels for the 8 immunized monkeys decreased from 50.6% on day 10 after CAMP challenge to 36.5% on day 17, then stabilized, averaging 36.7% on day 21 and increasing to 48.5% by day 31 after CAMP challenge. Three of the 8 monkeys experienced reductions in hematocrit of > 50%. The hematocrit levels of the 3 naïve monkeys also ANEMIA IN AOTUS MONKEYS WITH MALARIA decreased to a low of 38.6 on day 17 after challenge, but then increased to 47.3% on day 21. All 3 of the naïve monkeys were administered mefloquine on day 12 or 13 to treat elevated parasitemia; none experienced a 50% reduction in hematocrit. None of the immunized monkeys was treated. The 2 immune monkeys with the highest parasitemias during the CAMP challenge (monkey 12765 at 9,890 parasites/L and monkey 12763 at 10,920 parasites/L) also had the largest decreases in hematocrit referent to the day 10 baseline during the challenge (59.6% decrease and 51.8% decrease, respectively) ( Table 1 ). In spite of these decreases, the hematocrit levels in both these animals returned to normal without treatment by day 35 (49% and 50%, respectively). Mean day of highest parasitemia among the 9 infected monkeys (immunized and controls combined) was day 12.3 versus day 18.8 for lowest hematocrit (P ‫ס‬ 0.001, t-test). The 2 immunized monkeys that did not become infected had the least percentage decrease in hematocrit.
Vaccine trial 1-first challenge. During the 28-day followup period after the first P. falciparum challenge, 6 of the 32 monkeys under study required treatment for low hematocrit levels; another 21 were treated for parasitemia ( Table 2 ). The mean day of treatment for monkeys treated for high parasitemia was day 10.9 (95% confidence limit [CL] ‫ס‬ 10.5, 11.4), whereas the mean day of treatment for depressed hematocrit occurred on day 16.7 (95% CL ‫ס‬ 12.8, 20.5; P ‫ס‬ 0.012, 2-tailed t-test). Because monkeys treated for elevated parasitemia received drug before they had the opportunity to become anemic, the following comparison is restricted to those monkeys treated for decreased hematocrit versus those not treated (n ‫ס‬ 5). For those monkeys treated for low hematocrit levels, the mean low hematocrit was 19.2% (95% CL ‫ס‬ 16.6, 21.7), whereas the mean low hematocrit for those monkeys not treated (n ‫ס‬ 5) was 36.6% (95% CL ‫ס‬ 26.6, 46.6), P ‫ס‬ 0.007 (2-tailed t-test).
We also looked for an association between an individual monkey's maximum parasitemia and its minimum hematocrit level by means of simple linear regression. In many monkeys treated for elevated parasitemia, hematocrit levels continued to decrease even after treatment. We therefore analyzed the data in 2 ways: first, maximum parasitemia versus minimum hematocrit recorded anytime during the 28-day follow-up, and second, maximum parasitemia versus minimum hematocrit recorded before treatment. Maximum parasitemia and minimum hematocrit recorded any time (case 1) were not correlated (case 1, r 2 ‫ס‬ 0.011, P ‫ס‬ 0.25). There was a modest association between maximum parasitemia and minimum hematocrit before treatment (case 2, r 2 ‫ס‬ 0.336, P < 0.0009); high maximum parasitemia predicted high minimum hematocrit levels.
The minimum hematocrit levels in monkeys receiving EBA-175 in either or both forms (DNA vaccine or recombinant protein vaccine, n ‫ס‬ 16, mean minimum hematocrit ‫ס‬ * Monkeys were previously infected 7 times with FVO strain blood stage P. falciparum.
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The 3 control monkeys were naïve. Max density ‫ס‬ maximum parasite density (parasites/L) observed during the follow-up period; max day ‫ס‬ day of maximum parasitemia; min HCT ‫ס‬ minimum hematocrit observed during follow-up period; min day ‫ס‬ day of minimum parasitemia; decrease ‫ס‬ percentage decrease in hematocrit levels from prestudy baseline. * Max para ‫ס‬ maximum parasitemia; max day ‫ס‬ day of maximum parasitemia (300,000 parasites/L); min HCT ‫ס‬ minimum hematocrit level; min day ‫ס‬ day of minimum hematocrit level; Dv ‫ס‬ P.f. EBA DNA vaccine; HCT ‫ס‬ 50% decrease in hematocrit from preinfection baseline; para ‫ס‬ parasitemia; Pv ‫ס‬ P.F. EBA protein vaccine; NT ‫ס‬ not treated for either elevated parasitemia or decreased hematocrit, but treated as per protocol at the end of the 28-day follow-up period; Dc ‫ס‬ DNA vaccine control; Pc ‫ס‬ adjuvant control; n ‫ס‬ nothing; P.f. ‫ס‬ Plasmodium falciparum. 28) were compared with the hematocrit levels of monkeys not receiving EBA-175 (n ‫ס‬ 16, mean minimum hematocrit ‫ס‬ 32.4). No association between minimum hematocrit levels and receipt of EBA-175 vaccine was found (P ‫ס‬ 0.194; power to resolve a true difference of 4.4 was 24%, whereas a true difference of 9.5 would yield a power of 80%).
One striking difference in the development of anemia was between the DNA prime-protein boost (Dv_Pv) and the recombinant protein prime and boost (Pv_Pv) groups. The Pv_Pv group had slightly higher levels of antibodies by enzyme-linked immunosorbent assay after the boost (geometric means, 520,651 versus 801,189, P ‫ס‬ 0.35, t-test), and slightly lower peak parasitemias (166,492 versus 137,670, P ‫ס‬ 0.73, t-test) than did the Dv_Pv group. One animal in each group reached the parasitemia threshold for treatment of 300,000 parasites/L blood, but 3 of the 4 monkeys in the Pv_Pv group and none of the monkeys in the Dv_Pv group developed > 50% reduction in hematocrit. Among the monkeys that did not reach the parasitemia threshold, the minimum hematocrit levels in the 3 monkeys in the Pv_Pv group were significantly lower (P ‫ס‬ 0.037, t-test on log-transformed values) than in the Dv_Pv group (19, 21 , and 23 versus 27, 29, and 40, means of 21 and 32, respectively).
Vaccine trial 1-second challenge. Nine months after the first challenge, and 8 months after the last dose of mefloquine, the 24 monkeys (12 previously immunized with EBA-175, 12 previously controls) were rechallenged with 10 5 P. falciparum-parasitized erythrocytes. During the 28-day follow-up period, they were monitored daily for parasitemia, hematocrit levels, and reticulocyte count (Table 3) , and they were monitored once every 3 days for IgG on the surface of their erythrocytes (DAT). All monkeys became parasitemic, but none required treatment for parasitemia exceeding 300,000 parasites/L. However, 11 required treatment for reduced hematocrit levels; 7 of 12 previous controls and 4 of 12 previously immunized with EBA-175 vaccine (P ‫ס‬ 0.22, chi-square test). Mean maximum parasitemia was 4,820 parasites/L (95% CL ‫ס‬ 1,899, 7,742). The mean day on which maximum parasitemia occurred was day 14.4 (95% CL ‫ס‬ 12.9, 15.9). The mean minimum hematocrit level was 30.6% (95% CL ‫ס‬ 27.3, 33.9), and the mean day of minimum hematocrit level was day 21.3 (95% CL ‫ס‬ 20, 22.8). Mean maximum corrected reticulocyte count was 4.5% (95% CL ‫ס‬ 3.8, 5.2), and the mean day of maximum corrected reticulocyte count was day 24.9 (95% CL ‫ס‬ 22.7, 27). Direct antibody tests were performed on days 1, 3, 6, 9, 12, 16, 18, 21, 25, and 28. The DAT was not performed again after a monkey was treated. All DATs were negative for the presence of IgG on the surface of erythrocytes.
When daily parasitemia, hematocrit levels, and reticulocyte values were plotted for each monkey, a pattern emerged suggesting that regardless of hematocrit level, reticulocyte counts did not begin to increase until parasitemia density had fallen below ∼ 100 parasites/L. This was seen in 17 of 24 of the monkeys. Two examples, one from a monkey treated for depressed hematocrit and the other from an untreated monkey, are shown in Figure 1 .
In order to establish a baseline corrected reticulocyte value, the mean of the daily reticulocyte counts from day 3 to day 6 was calculated for each monkey. Any reticulocyte count from day 7 to day 28 that was above that mean plus 2 standard deviations was designated as "elevated." For each monkey exhibiting elevated reticulocyte counts (15 of 24), we calculated the mean hematocrit level and the mean parasitemia for the day before the elevated reticulocyte counts. We also calculated the mean hematocrit and parasitemia counts for the days before each day with a nonelevated reticulocyte count. The mean hematocrit for days preceding an elevated reticulocyte count was 41.7% versus 46.7% for those days preceding a day with a nonelevated reticulocyte count (P ‫ס‬ 0.019, paired t-test). Mean parasitemias for the same days were 118 parasites/L (elevated reticulocyte count) versus 507 parasites/L (nonelevated reticulocyte count) (P ‫ס‬ 0.018, paired t-test).
Vaccine trial 2-challenge. During the 28-day follow-up period after P. falciparum challenge, 6 of the 18 monkeys required treatment for low hematocrit levels, and another 11 were treated for elevated parasitemia ( Table 4 ). The mean day for treatment for elevated parasitemia was day 11.9 (95% CL ‫ס‬ 14.3, 9.5), and the mean day of treatment for decreased hematocrit was day 20.8 (95% CL ‫ס‬ 23.4, 18.3; P ‫ס‬ 0.001, * Aotus nancymae previously infected once with 10 4 P. falciparum were rechallenged with 10 5 P. falciparum-parasitized Aotus erythrocytes 9 months after the first challenge, and they were followed for 28 days. The first entry identifies immunogen used in first 3 immunizations, and the second entry identifies the immunogen or immunogens used in the fourth immunization. All monkeys treated before the end of the 28-day follow-up period were treated for a decrease in hematocrit levels of > 50% of baseline, and none were treated for elevated parasitemia. max para ‫ס‬ maximum parasitemia observed during the 28-day followup period; max day ‫ס‬ day of maximum parasitemia; min HCT ‫ס‬ minimum hematocrit observed during the 28-day follow-up period; min day ‫ס‬ day of minimum hematocrit; max retic ‫ס‬ maximum reticulocyte count during the 28-day follow-up period; day retic ‫ס‬ day of maximum reticulocyte count; day of treatment ‫ס‬ day of treatment for anemia; Dv ‫ס‬ P.f. EBA DNA vaccine; NT ‫ס‬ not treated for either elevated parasitemia or decreased hematocrit level, but treated per protocol at the end of the 28-day follow-up period; Pv ‫ס‬ P.f. EBA protein vaccine; DC ‫ס‬ DNA vaccine control; Pc ‫ס‬ adjuvant control; n ‫ס‬ nothing; P.f. ‫ס‬ P. falciparum .
2-tailed t-test).
Only one monkey (monkey 1098, an immunized animal) completed the 28-day follow-up without requiring treatment for either elevated parasitemia or decreased hematocrit. Maximum parasitemia and minimum hematocrit recorded any time during the 28-day follow-up period were correlated (r 2 ‫ס‬ 0.436, P ‫ס‬ 0.002). The correlation strengthened when maximum parasitemia and minimum hematocrit recorded before treatment were evaluated (r 2 ‫ס‬ 0.681, P < 0.0009). As in the first trial, high maximum parasitemia predicted high minimum hematocrit levels. The minimum hematocrit levels of the monkeys receiving EBA-175 (31.7, 95% CL 36.6, 26.7) versus those not receiving it (37.8, 95% CL 43.7, 31.9) were not different (P ‫ס‬ 0.158, 2-tailed t-test).
The parasitemia, hematocrit level, reticulocyte count, and platelet count plots for each monkey revealed that in 12 of 18 monkeys, reticulocyte count did not begin to rise until after the parasitemia had fallen to ∼ 100 parasites/L. These findings were consistent with those of vaccine trial 1-second challenge.
Blood counts were performed on days 2, 9, 17, and 24 of the postchallenge follow-up period (Table 5 ). Lymphocyte and monocyte counts decreased 44% and 42%, respectively, between day 2 and day 9 but rebounded to day 2 levels by day 17. Granulocyte and platelet counts decreased more slowly, but more markedly. By day 17, granulocyte and platelet counts dropped to 25% and 15% of day 2 values and did not rebound by day 24. Because CBCs were performed less frequently than were other hematologic tests, it was not clear whether granulocyte or platelet counts were associated with other measures, but they did not seem closely related to changes in parasitemia.
As we described above (vaccine trial 1, second challenge), we established a baseline corrected reticulocyte value by means of the mean daily reticulocyte counts from day 1 to day 6. As before, any reticulocyte count from day 7 to day 28 that was above that mean plus 2 standard deviations was arbitrarily designated as "elevated." The mean hematocrit for days preceding an elevated reticulocyte count was 40.2% versus 45.3% for those days after a day with a nonelevated reticulocyte count (P ‫ס‬ 0.08, paired t-test). Mean parasitemia for the same days were 5,968 parasites/L (elevated reticulocyte count) versus 38,927 parasites/L (nonelevated reticulocyte count) (P ‫ס‬ 0.006, paired t-test).
Modified DATs for IgG and complement component C3d were performed on days 1, 4, 8, 13, 16, 20, 24 , and 28 of the 28-day follow-up period; all tests in all monkeys were negative.
DISCUSSION
Anemia is a frequent and often serious complication in P. falciparum malaria. 11 This malaria anemia could be caused by any of 3 mechanisms: lysis of infected erythrocytes, lysis or sequestration of noninfected erythrocytes, and suppression of hematopoiesis. Work by others has made it clear that more than one of these mechanisms is involved. [12] [13] [14] It is immediately clear from the data obtained in the first study (repeated infections) that lysis of infected erythrocytes alone cannot account for the often marked decreases in hematocrit. For example, in the Aotus subjected to repeated infection, 3 animals with maximum parasite densities never exceeding 11,000 parasites/L experienced decreases in hematocrit levels of between 50% and 60%. This means ∼ 0.2% of circulating erythrocytes were parasitized, ∼ 250 times too few erythrocytes to explain the removal from circulation of more than half these animals' erythrocytes. Minimum hematocrit levels were, on average, reached between days 17 and 21. Such a rapid onset of anemia indicates that suppression of bone marrow alone could not produce these dramatic decreases in hematocrit. If all erythropoietic activity ceased on day 0 of the challenge, by day 20, the monkey should have lost only ∼ 20% of its erythrocytes-clearly not enough to explain a 50% decrease in the hematocrit. Because dyserythropoiesis cannot account for the entire decrease in hematocrit does not mean, however, that it is not a contributing factor. Because neither lysis of parasitized erythrocytes nor dyserythropoiesis seems able to account for the entire decrease in hematocrit levels, lysis or removal of noninfected erythrocytes is invoked as the major contributor to the anemia.
In 3 subsequent trials with P. falciparum blood stage challenges, we evaluated the following: (1) whether immunemediated lysis of the noninfected erythrocytes could be the mechanism driving the severe decreases in hematocrit in the Aotus, (2) any association between parasitemia density and hematocrit; (3) any association among parasitemia, hematocrit level, and reticulocytosis; (4) and association of parasitemia and anemia on other blood cell types.
By use of fresh whole blood collected during the challenge phase of the rechallenge of vaccine trial 1, we tested for the presence of IgG on erythrocyte surfaces with a protein A/protein G column system. All samples from all animals were negative. During the challenge in vaccine trial 2, we tested the erythrocytes for both IgG and complement fragment C3d by using specific antibody. In all cases, the tests were negative for both. DAT studies of human volunteers in malarious areas have not been entirely consistent. Facer and others 15 studied 162 Gambian children with variable malaria histories and found that ∼ 50% of those with past or current malaria infection had C3d, IgG, or both on their erythrocytes. There was no correlation between DAT positivity and parasitemia density at the time they sought care, but they did observe a significant association between a positive DAT and a hematocrit level < 30%. Abdalla and Weatherall 16 studied 134 Gambian children and found that 52 had positive DATs (twice as many as a result of C3 as IgG). They also found, however, that hemoglobin levels and reticulocyte counts were the same in these children whether they had positive or negative DATs. Merry and others 17 studied 83 P. falciparum malaria patients in Thailand. There was no difference in the number of IgG molecules per erythrocyte between uncomplicated malaria cases and healthy controls. The authors thought that this low level of coating would not have caused accelerated destruction of these cells. They also found no association between the presence of IgG on the surface of erythrocytes and anemia.
In their study of anemia in young Gambian children, Abdalla and others 2 were able to divide the subjects into 3 groups: acute malaria (brief history, high parasitemia, hemoglobin Ն 8 g/dL), anemic acute malaria (brief history, high parasitemia, hemoglobin < 8 g/dL), and chronic malaria (no history of acute illness, low parasitemia, and hemoglobin < 6 g/dL). The experimental malaria induced in the Aotus in this study most closely parallels the first group. Monkeys being challenged for the first time become parasitemic rapidly, and most required drug therapy by day 12 as a result of parasitemias exceeding 300,000 parasites/L. In those animals not receiving treatment for elevated parasitemia, the lowest hematocrit level recorded occurred ∼ 6 to 9 days later than the maximum parasitemias. Simple linear regression analysis suggested that monkeys with high maximum parasitemias tended to have less anemia, but this assessment is badly confounded by the fact that monkeys with high parasitemias were treated, whereas those with low parasitemias were not. This means that only animals with low parasitemias remain parasitemic after approximately day 12, and this may account for the differences in incidence and intensity of anemia. Carvalho and others 18 also had a case of severe anemia among 5 Aotus infulatus infected with P. falciparum. Three of the animals 8 -* The first entry identifies the immunogen used in first 3 immunizations, and the second entry identifies immunogen or immunogens used in the fourth immunization. max para ‫ס‬ maximum parasitemia observed during the 28-day follow-up period; max day ‫ס‬ day of maximum parasitemia; min HCT ‫ס‬ minimum hematocrit levels observed during the 28-day follow-up period; max retic ‫ס‬ maximum reticulocyte count during the 28-day follow-up period; day retic ‫ס‬ day of maximum reticulocyte count; Dv ‫ס‬ P.f. EBA DNA vaccine; Pv ‫ס‬ P.f. EBA protein vaccine; HCT ‫ס‬ hematocrit > 50% below baseline; Para ‫ס‬ parasitemia > 300,000 parasites/L; Dc ‫ס‬ DNA vaccine control; Pc ‫ס‬ adjuvant control; n ‫ס‬ nothing; NT ‫ס‬ not treated for either elevated parasitemia or decreased hematocrit levels, but treated per protocol at the end of the 28-day follow-up period; P.f. ‫ס‬ P. falciparum; Day HCT ‫ס‬ day of minimum hematocrit.
were intact, and 2 were splenectomized. The 2 splenectomized animals rapidly developed high parasitemias (> 5%) by day 10 and required treatment; they did not become anemic. The one intact animal that controlled its parasitemia such that it did not require treatment developed a profound anemia (hematocrit of 13%).
Splenic enlargement, often associated with nonacute parasitemias, may itself play a part in the induction of anemia. Looareesuwan and others 19 showed that clearance of noninfected radiolabeled erythrocytes was increased in P. falciparum-infected humans only when splenomegaly was present. Infected humans free of splenomegaly had normal clearance rates unless treated with antimalarial drugs, and then clearance of noninfected cells also increased.
Reticulocyte counts in vaccine trial 1-second challenge were associated statistically with both hematocrit and parasitemia, particularly the latter. The mean hematocrit level calculated for days with normal reticulocyte counts was about 5 percentage points higher than the mean hematocrit calculated from days with elevated reticulocyte counts (46.7 versus 41.7 and 45.3 versus 40.2 in the 2 studies). In both studies in which reticulocyte count data were collected, the mean parasitemia on days with elevated reticulocyte counts was much lower (4.3-or 6.5-fold) than on days with nonelevated reticulocytes. In addition, in 29 (69%) of 42 monkeys across 2 different studies, reticulocyte counts did not rise above normal until the parasitemia had dropped below ∼ 100 parasites/L, irrespective of hematocrit levels. The most obvious explanation for this is that a high parasitemia suppresses either the production or the release of reticulocytes in spite of the presence of an anemia driving reticulocyte release.
The appearance of the reticulocytosis was similar to that documented by Abdalla and others.
2 Those patients they classified as having "acute malaria" (short history and high parasitemia) experienced a drop in hemoglobin when parasites disappeared as a result of drug treatment. They also observed that reticulocytosis developed 5 days after treatment-that is, after parasitemia had fallen. They also studied the bone marrow of the patients with acute malaria and found the relative number of erythroid precursors to be normal or low, and erythropoiesis to be normoblastic. Bone marrow from patients with chronic malaria, on the other hand, showed significant evidence of dyserythropoiesis.
CBC data, collected at 4 points during the 28-day follow-up period in vaccine trial 2, showed changes in white blood cell populations. Lymphocytes and monocyte counts dropped modestly between days 2 and 9, but they recovered by day 17. Granulocyte and platelet levels, on the other hand, showed marked drops through day 17, with no or incomplete recovery by day 24. Kakoma and others 20 studied changes in blood cell values in Aotus nancymai monkeys infected with P. falciparum. They tested the animals on day 0, 7, and 14 after challenge, and we tested on days 2, 9, 17, and 24. They also noted severe thrombocytopenia, particularly on day 14. This is similar to our finding of significant thrombocytopenia on day 17 after challenge. They noted, as did we, that lymphocyte numbers decreased earlier than platelets and rebounded by 14 or 17 days. In a study of radiolabeled platelet distribution in humans, Aster 21 found that a significant fraction of the platelets can pool in the spleen. In cases of hypersplenism (Aotus experience enlarged spleens when infected with P. falciparum), that fraction can increase to 50% or even 90%.
Twenty-five (30.5%) of 82 of the P. falciparum infections in Aotus described in this study resulted in a > 50% decrease in hematocrit. Lysis of infected erythrocytes is insufficient to explain the removal of so many erythrocytes from circulation. In fact, 18 of the 32 monkeys experiencing Ն 50% decreases in hematocrit had parasitemia that never exceeded 100,000 parasites/L or ∼ 2% of erythrocytes infected. This is ∼ 1.5 orders of magnitude too few to explain the removal of 50% of circulating erythrocytes. In the repeated-infection experiment, 3 of 8 monkeys experienced a > 50% decrease in hematocrit levels, yet no maximum parasitemia exceeded 11,000 parasites/L, 2.5 orders of magnitude too few infected erythrocytes to explain the anemia. Although the mean day of maximum parasitemia for the 82 infections was day 12.5 (95% CL ‫ס‬ 11.9, 13.1), the mean day of minimum hematocrit occurred later at day 18.8 (95% CL ‫ס‬ 17. 8, 19.9) . This is too soon for marrow suppression to explain the observed loss of erythrocytes.
Because neither lysis of infected erythrocytes nor marrow suppression alone can explain the anemia, we suggest that lysis of uninfected erythrocytes is the major contributor to the anemia. The failure to find either antibody or complement on the surface of erythrocytes harvested while the monkeys were infected indicates that an antibody-mediated or C3d-mediated lysis was not occurring. Although lysis of infected and noninfected erythrocytes seems to be the major contributor to the anemia, there is evidence of marrow suppression. The appearance of a reticulocytosis that correlated only with low, and not high, parasite densities, indicating that high parasite densities suppress the development or release of reticulocytes from the marrow. This suppression may also explain the thrombocytopenia seen in some of the monkeys. The dramatic decrease in platelets may also be caused by pooling in the enlarged spleens often seen in P. falciparum-infected Aotus monkeys.
Because most of the P. falciparum infections occurred in the context of EBA-175 vaccine trials, we looked for an association between this specific vaccine immunogen and anemia, but we did not find one. In addition, an efficacy trial in Aotus of another vaccine immunogen (merozoite surface protein 1) showed similar instances of marked anemia. 22 Also, some of the cases of anemia reported here were seen in monkeys not immunized with a specific vaccine immunogen, but rather in animals subjected only to repeated infection with P. falciparum. It is our view that anemia onset is related to the acquisition by the monkey of sufficient immunity to partially control its parasitemia. We believe that this partial control results in a continuing low-level parasitemia that is the proximate cause of the anemia. This would mean that the anemia could be induced by any antigen or agent capable of inducing a modicum of immunity and that the anemia is not associated with one or another specific immunogen. The mechanism we propose here may be a major contributor to the anemia seen in children in Africa at the end of the intense transmission season. 23 If this is the case, it will be extremely important to monitor hemoglobin status during trials of malaria vaccines that are designed not to prevent blood stage infection, but rather to limit it. 24 this study. We also thank Dr. Louis H. Miller for providing the FVO strain P. falciparum used in the Aotus nancymae challenges and Dr. William Collins for kindly providing the CAMP strain of P. falciparum used in the heterologous challenge of Aotus lemurinus lemurinus.
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